Peripheral Neuropathy in Cancer Patients- Multifactorial Contributors to Dose Limiting and Chronic Toxicity
Authors:
Preprint
Abstract
Background and Objective Chemotherapy-induced peripheral neuropathy (CIPN) is a complex and dose-limiting toxicity of anticancer treatments with chronic symptoms leading to increased disability and reduced quality of life. The present study evaluated clinical risk factors associated with development of chronic, severe and dose-limiting CIPN, utilising a comprehensive multi-modal battery of neuropathy assessment. Methods Baseline clinical risk factors were investigated in patients who had completed neurotoxic chemotherapy (including taxanes, platinums and haematological cancer therapies). CIPN was assessed using neurological evaluation (Total Neuropathy Score, sural nerve conduction studies), patient reported outcome measure (EORTC QLQ-CIPN20), and clinically graded neuropathy (NCI-CTCAE). Multivariate models of risk factors associated with development of chronic, severe and dose-limiting CIPN were evaluated using backwards stepwise regression model building. Results The study recruited 903 patients (age 61 (IQR 50-69) years) who were assessed 12 (IQR 6-24) months post neurotoxic treatment. 73% of patients presented with CIPN at time of assessment, with 37% having moderate to severe symptoms. 32% of patients experienced neurotoxic treatment dose modification due to CIPN. Across the various CIPN assessment approaches, risk factors for chronic CIPN included older age, diabetes diagnosis, higher BMI and prior exposure to neurotoxic treatment (all PDiscussion This study identified baseline clinical risk factors associated chronic, severe and dose-limiting CIPN. Closer monitoring of these vulnerable cohorts will allow for timely CIPN management, including referral pathways to intervention and rehabilitation therapies which will ultimately lead to improved CIPN morbidity.Keywords
This publication has 62 references indexed in Scilit:
- Female sex is a risk factor for painful diabetic peripheral neuropathy: the EURODIAB prospective diabetes complications studyDiabetologia, 2023
- Systematic review of long-term chemotherapy-induced peripheral neuropathy (CIPN) following adjuvant oxaliplatin for colorectal cancerSupportive Care in Cancer, 2021
- Diabetes mellitus as a risk factor for chemotherapy-induced peripheral neuropathy: a meta-analysisSupportive Care in Cancer, 2021
- Weekly Paclitaxel-Induced Neurotoxicity in Breast Cancer: Outcomes and Dose ResponseThe Oncologist, 2021
- Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral NeuropathyJAMA Network Open, 2021
- Taxane-induced peripheral neuropathy: differences in patient report and objective assessmentSupportive Care in Cancer, 2020
- Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon CancerJAMA Oncology, 2019
- Risk factors for chemotherapy‐induced peripheral neuropathy in patients receiving taxane‐ and platinum‐based chemotherapyBrain and Behavior, 2019
- Disease burden and pain in obese cancer patients with chemotherapy-induced peripheral neuropathySupportive Care in Cancer, 2017
- Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IVSupportive Care in Cancer, 2012